16 Facts About Zolpidem

Zolpidem, sold under the brand name Ambien, among others, is a medication primarily used for the short-term treatment of sleeping problems.

Zolpidem is a nonbenzodiazepine which acts as a sedative and hypnotic.

Zolpidem is a GABAA receptor agonist of the imidazopyridine class.

Zolpidem was approved for medical use in the United States in 1992.

Zolpidem is a Schedule IV controlled substance under the Controlled Substances Act of 1970.

Related searches

Zolpidem is labelled for short-term treatment of insomnia at the lowest possible dose.

Zolpidem has not been assigned to a pregnancy category by the FDA.

Zolpidem is recommended for use during pregnancy only when benefits outweigh risks.

Zolpidem is a ligand of high-affinity positive modulator sites of GABAA receptors, which enhances GABAergic inhibition of neurotransmission in the central nervous system.

Zolpidem has about 10-fold lower affinity for the a2- and a3- subunits than for a1, and no appreciable affinity for a5 subunit-containing receptors.

Zolpidem has no affinity for ?1 and ?3 subunit-containing receptors and, like the vast majority of benzodiazepine-like drugs, it lacks affinity for receptors containing a4 and a6.

Zolpidem was used in Europe starting in 1988, and was brought to market there by Synthelabo.

Zolpidem has potential for either medical misuse when the drug is continued long term without or against medical advice, or for recreational use when the drug is taken to achieve a "high".

Zolpidem was used by Australian Olympic swimmers at the London Olympics in 2012, leading to controversy.

Zolpidem received widespread media coverage in Australia after the death of a student who fell 20 metres from the Sydney Harbour Bridge while under the influence of zolpidem.

Zolpidem has been studied in persistent vegetative states with unclear effect.